Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis

Keat, Andrew; Gaffney, Karl; Gilbert, Annie; Harris, C.; Leeder, Jane

doi:10.1093/rheumatology/ken010

Cited by 43 publications

(45 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The level of employment of those who were of working age in this cohort of AS patients (60%) was approximately 14% lower than the current UK national average of those of working age (30). Similarly, a Dutch study demonstrated employment rates of 54.2% for an AS cohort, a significant reduction of 11% compared with the Dutch workingage population (10).…”

Section: Discussionmentioning

confidence: 54%

See 1 more Smart Citation

Impact of ankylosing spondylitis on work in patients across the UK

Healey

Haywood

Jordan

et al. 2010

Scandinavian Journal of Rheumatology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 54%

“…Hence the results are likely to be more generalizable than other studies. For example, previous UK-based studies have used the National Ankylosing Spondylitis Society (NASS) or just one centre to draw their sample from (13,30).…”

Section: Discussionmentioning

confidence: 99%

Impact of ankylosing spondylitis on work in patients across the UK

Healey

Haywood

Jordan

et al. 2010

Scandinavian Journal of Rheumatology

View full text Add to dashboard Cite

show abstract

“…18 Studies on the effects of TNF antagonists on work limitations in RA patients have had either a retrospective observational design or a clinical primary outcome with work data examined as a secondary outcome. [19][20][21][22][23][24] These studies show an improvement in employability and a reduction in the workday losses in patients with RA and ankylosing spondylitis through the treatment with biologics (TNF antagonists). 17,23,25 In the present study, we examined the correlation between changes in work productivity and disease activity.…”

Section: Discussionmentioning

confidence: 99%

Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis

Furuya

Kasama

Isozaki³

et al. 2013

JMDH

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a significant cause of work disability and job loss. The resulting economic burden experienced by patients has received considerable research attention. This research assesses the effect of tumor necrosis factor (TNF) antagonists (infliximab, etanercept) on the ability of RA patients living in Japan to work and participate in society. A total of 42 patients with active RA were enrolled and given biological therapy for 12 months (mo). Of these patients, 14 were employed full-time, 6 were employed part-time, and 22 were not employed. Twenty-six patients were given infliximab, and sixteen were given etanercept. The amount of domestic labor performed before the biologics served as a baseline and was assigned a value of 0%. After treatment with biologics, the productivity was evaluated using the visual analog scale (VAS; -100 to +100 mm). The administration of TNF antagonists to RA patients who exhibited an insufficient response to medical treatment significantly improved the Disease Activity Score 28 (DAS 28) after both 6 mo and 12 mo (P , 0.0001). A significant correlation was found between the improvement in their DAS 28 and improvements in their work situation (Productivity VAS) (P , 0.05). Of particular interest is the significant correlation between the values of baseline mHAQ and the percent changes of Productivity VAS that was observed after 6 mo and 12 mo (P , 0.05). Our findings indicate that medical treatment of RA with TNF antagonists improves the patients' ability to perform their jobs and housekeeping. Because loss of productivity is an important contributor to the indirect costs of RA, our findings are relevant for the pharmacoeconomic assessment of treatments.

show abstract

“…Several instruments have been developed, but they provide different results (2,7,8,17,(21)(22)(23)(24). Among the instruments for presenteeism assessment, a self-reported measure of productivity at work might be a relevant indicator for future adverse work outcomes, like sick leave, because it accounts not only for symptoms such as pain, stiffness, and fatigue, but also for the effects of these symptoms on working speed, concentration, and interpersonal interactions.…”

Section: Introductionmentioning

confidence: 99%

Longitudinal Analyses of Presenteeism and Its Role as a Predictor of Sick Leave in Patients With Ankylosing Spondylitis

Tran‐Duy

Nguyen

Thijs

et al. 2015

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. To investigate, in a cohort of patients with ankylosing spondylitis (AS) adequately treated with infliximab, changes over time in presenteeism and the role of presenteeism relative to that of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Bath Ankylosing Spondylitis Functional Index (BASFI) in predicting sick leave. Methods. Data were analyzed from 71 patients with paid work and taking a stable dose of infliximab participating in a 96-week study with 5 assessment points. Covariates included presenteeism, sick leave, time, sex, age, BASDAI, BASFI, Bath Ankylosing Spondylitis Metrology Index, and part-or full-time work. Presenteeism represented the AS impact on productivity (by visual analog scale, range 0-10, where 10 5 completely unproductive). Sick leave represented the number of days absent from work due to AS in the last 6 months. A linear mixed-effects model for presenteeism, and hurdle and zero-inflated count models for sick leave were explored. Results. Mean 6 SD presenteeism ranged from 2.2 6 2.2 to 3.8 6 7.8, and sick leave occurred in 8-17% of the patients during the 6-month period. Presenteeism positively correlated with BASDAI and BASFI, but was not significantly influenced by time. The chance of incurring sick leave was affected by presenteeism but not by BASDAI and BASFI. Conditional on being absent from work, the effect of presenteeism on the length of sick leave (in days) was much stronger than BASDAI and BASFI. For presenteeism ‡5, an increase of 1 unit in presenteeism yielded an increase by 36-40% (or 2-12 days) in the length of sick leave during the following 6 months. Conclusion. Presenteeism, even measured by a simple visual analog scale, was an important factor to explain future sick leave.

show abstract

Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis

Abstract: Treatment of active AS with TNF blockade appears to be associated with improved capacity for work.

Cited by 43 publications

References 21 publications

Impact of ankylosing spondylitis on work in patients across the UK

Impact of ankylosing spondylitis on work in patients across the UK

Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis

Longitudinal Analyses of Presenteeism and Its Role as a Predictor of Sick Leave in Patients With Ankylosing Spondylitis

Contact Info

Product

Resources

About